Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. The company is headquartered in Radnor, Pennsylvania and currently employs 1,487 full-time employees. The company went IPO on 2020-12-11. The company accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. The company delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. The company offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
How did CERT's recent EPS compare to expectations?
The most recent EPS for Certara Inc is $0.09, not beating expectations of $0.11.
How did Certara Inc CERT's revenue perform in the last quarter?
Certara Inc revenue for the last quarter is $0.09
What is the revenue estimate for Certara Inc?
According to 12 of Wall street analyst, the revenue estimate of Certara Inc range from $114.77M to $102.51M
What's the earning quality score for Certara Inc?
Certara Inc has a earning quality score of B+/57.1345. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Certara Inc report earnings?
Certara Inc next earnings report is expected in 2026-05-27
What are Certara Inc's expected earnings?
Certara Inc expected earnings is $105.25M, according to wall-street analysts.
Did Certara Inc beat earnings expectations?
Certara Inc recent earnings of $103.64M does not beat expectations.